Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
收藏DataCite Commons2025-12-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012071/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
提供机构：
Vivli
创建时间：
2025-12-05
